Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™).

ABSTRACT: BACKGROUND:Telavancin-a lipoglycopeptide antibacterial agent active against Gram-positive pathogens including methicillin-sensitive and -resistant Staphylococcus aureus (MRSA)-is approved in the USA for once-daily intravenous use. This registry study captured patient characteristics, prescribing patterns, and treatment outcomes associated with telavancin use in real-world clinical practice. OBJECTIVE:This prospective, multicenter, observational study will characterize current real-world practice patterns for the use of telavancin in the USA by describing demographic and clinical conditions, examining the process of care and rationale for use, and describing the clinical effectiveness and selected safety outcomes among patients treated with telavancin. METHODS:The Telavancin Observational U

SUBMITTER: Bressler AM 

PROVIDER: S-EPMC6879699 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature